EUVIMEDEUVIMED entdecken
Crossref

Discovery of Substituted 2-oxoquinolinylthiazolidin-4-one Analogues as Potential EGFRK Inhibitors in Lung Cancer Treatment

Soniya Naik, Vasu Soumya, Shivlingrao N Mamledesai, M Manickavasagam, Prafulla Choudhari, Sanket Rathod

Drug Research · 2024-06 · 74 (05) · 227-240

DOI: 10.1055/a-2305-2789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, online erschienen am 03.06.2024. Verfasst von Soniya Naik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chenn…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Molecular Docking Simulation, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer and the chemotherapeutic drugs available have high toxicity and have reported side effects hence, there is a need for the synthesis of novel drugs in the treatment of cancer.

Methods

The current research work dealt with the synthesis of a series of 3-(3-acetyl-2-oxoquinolin-1-(2H)-yl-2-(substitutedphenyl)thiazolidin-4-one (Va-j) derivatives and evaluation of their in-vitro anticancer activity. All the synthesized compounds were satisfactorily characterized by IR and NMR data. Compounds were further evaluated for their in-vitro anticancer activity against A-549 (lung cancer) cell lines. The in-vitro anticancer activity was based upon the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay method.

Results

The synthesized compounds exhibited satisfactory anticancer properties against the A-549 cell line. The compound (Vh) showed the highest potency amongst the tested derivatives against the A-549 cell line with IC50 values of 100 µg/ml respectively and was also found to be more potent than Imatinib (150 µg/ml) which was used as a standard drug. Molecular docking studies of the titled compounds (Va-j) were carried out using AutoDock Vina/PyRx software. The synthesized compounds exhibited well-conserved hydrogen bonds with one or more amino acid residues in the active pocket of the EGFRK tyrosine kinase domain (PDB 1m17).

Conclusion

Among all the synthesized analogues, the binding affinity of the compound (Vh) was found to be higher than other synthesized derivatives and a molecular dynamics simulation study explored the stability of the docked complex system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMolecular Docking SimulationErbB ReceptorsLung NeoplasmsHumansStructure-Activity RelationshipProtein Kinase InhibitorsCell Line, TumorA549 CellsThiazolidinesDrug Screening Assays, AntitumorCell Proliferation

Substanzen

Antineoplastic AgentsErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsThiazolidines

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India.
  • Department of Pharmaceutical Chemistry, P.E.S's Rajaram and Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, Goa, India.
  • Department of Oncology, SRMC & RI, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, India.
  • Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India.

Zitieren

APA

Naik, S., Soumya, V., Mamledesai, S. N., Manickavasagam, M., Choudhari, P., & Rathod, S. (2024). Discovery of Substituted 2-oxoquinolinylthiazolidin-4-one Analogues as Potential EGFRK Inhibitors in Lung Cancer Treatment. Drug Research, 74(05), 227-240. https://doi.org/10.1055/a-2305-2789

Vancouver

Naik S, Soumya V, Mamledesai SN, Manickavasagam M, Choudhari P, Rathod S. Discovery of Substituted 2-oxoquinolinylthiazolidin-4-one Analogues as Potential EGFRK Inhibitors in Lung Cancer Treatment. Drug Research. 2024;74(05):227-240. doi:10.1055/a-2305-2789

BibTeX
@article{Naik2024,
  author = {Naik, Soniya and Soumya, Vasu and Mamledesai, Shivlingrao N and Manickavasagam, M and Choudhari, Prafulla and Rathod, Sanket},
  title = {Discovery of Substituted 2-oxoquinolinylthiazolidin-4-one Analogues as Potential EGFRK Inhibitors in Lung Cancer Treatment},
  journal = {Drug Research},
  year = {2024},
  volume = {74},
  number = {05},
  pages = {227--240},
  doi = {10.1055/a-2305-2789}
}
Kostenlos starten →